
Please try another search
By Sam Nussey
TOKYO (Reuters) -Japan's Nintendo Co Ltd (TYO:7974) sold 23% fewer Switch (NYSE:SWCH) consoles in the April-June quarter than a year earlier following chip shortages, it said on Wednesday.
The Kyoto-based gaming company said it expected procurement to improve "from late summer towards autumn" and maintained its forecast to sell 21 million units in the year through end-March 2023.
"Demand remains stable in all regions," Nintendo said in a presentation.
Nintendo, the company behind "Super Mario", sold 3.43 million units of its Switch console in the quarter, down from from 4.45 million a year earlier. It sold 23.06 million units last year.
It forecasts the second annual sales decline for its hybrid home/portable Switch device, which is in its sixth year on the market.
The company last October launched an upgraded Switch model with an OLED screen to drive interest in the system.
First-quarter software sales declined by 8.6% to 41.4 million units, while operating profit fell 15% to 101.6 billion yen ($763 million), below analyst estimates.
Nintendo booked a 51.7 billion yen foreign exchange gain from the weaker yen.
Investors are gauging the unwinding of a gaming boom among consumers who had been stuck at home during pandemic lockdowns.
Sony (NYSE:SONY) Group Corp last week reported a 15% drop in PlayStation user engagement compared to a year earlier.
"Gaming is now bigger than ever, and a certain part of users stay on, but the party is certainly now over," said Serkan Toto, founder of game industry consultancy Kantan Games.
Upcoming Nintendo games to support demand into the year-end shopping season include "Splatoon 3", which will be released in September, and "Pokemon Scarlet and Violet" in November.
($1 = 133.2100 yen)
(Reuters) - Russia has failed to gain ground in cyberspace against Ukraine almost six months after its invasion of the country, the head of Britain's GCHQ intelligence service...
By David Shepardson WASHINGTON (Reuters) -General Motors Co and LG Energy Solution are considering a site in Indiana for a fourth U.S. battery cell manufacturing plant, a...
By Mrinalika Roy (Reuters) -Bluebird bio slumped nearly 15% on Thursday as investors fretted over sales potential of its newly approved ultra-rare blood disorder gene therapy that...
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review
Add a Comment
We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:
Enrich the conversation, don’t trash it.
Stay focused and on track. Only post material that’s relevant to the topic being discussed.
Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.
Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.